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Abstract
Secretory phospholipase A2 (sPLA2) is a critical component of insect and snake venoms and is secreted by mammalian
leukocytes during inflammation. Elevated secretory PLA2 concentrations are associated with autoimmune diseases and
septic shock. Many sPLA2’s do not bind to plasma membranes of quiescent cells but bind and digest phospholipids on the
membranes of stimulated or apoptotic cells. The capacity of these phospholipases to digest membranes of stimulated or
apoptotic cells correlates to the exposure of phosphatidylserine. In the present study, the ability of the phosphatidyl-L-
serine-binding protein, lactadherin to inhibit phospholipase enzyme activity has been assessed. Inhibition of human
secretory phospholipase A2-V on phospholipid vesicles exceeded 90%, whereas inhibition of Naja mossambica sPLA2
plateaued at 50–60%. Lactadherin inhibited 45% of activity of Naja mossambica sPLA2 and .70% of human secretory
phospholipase A2-V on the membranes of human NB4 leukemia cells treated with calcium ionophore A23187. The data
indicate that lactadherin may decrease inflammation by inhibiting sPLA2.
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Introduction
Secretory phospholipase A2 (sPLA2) is a nine-member family of
16–18 kDa enzymes with five to eight disulfide bonds. These
Ca
2+-dependent enzymes hydrolyze sn-2 esters of phospholipid
molecules via an Asp-His diad [1–3]. The action of sPLA2 occurs
in two phases. First, the sPLA2 binds to a bilayer and then the
bound molecule continues predominantly in scooting mode,
cleaving multiple phospholipid substrate molecules without
dissociating from the membrane [4]. A substantial portion of
membrane and phospholipid specificity is exhibited in the initial
binding step. Thus, one mechanism of inhibiting activity of
secretory phospholipase A2 is via competition for the initial
membrane binding sites.
Of the family of sPLA2’s, three are of particular interest in
relation to inflammation, namely group IIA (hsPLA2-IIA), group
V and group X. Group IIA (also known as synovial sPLA2 or non-
pancreatic PLA2) is a secreted phospholipase originally found and
purified from synovial fluid of rheumatoid arthritis patients and
correlates with sepsis as well as autoimmune disease [5–10]. The
basic group IIA sPLA2’s are highly selective for anionic
phospholipids, with phosphatidylserine (PS) as an important
phospholipid target for efficient plasma membrane docking
[4,11,12]. Comparably, group V is closely related to group IIA
[13], but more neutral and maintains efficient docking via a
tryptophan in the docking interface [14,15]. In a mechanistically
similar fashion, group X exhibits more hydrophobic residues
allowing docking to and hydrolysis of zwitterionic phospholipids
like phosphatidylcholine and is largely unaffected by PS exposure
[16]. Together, the native charge as well as interface residues
largely account for the preferred substrate of these three enzymes,
with group V and X more readily binding and cleaving
zwitterionic substrates and generating the gateway molecule of
eicosanoid synthesis, arachidonic acid, as compared to group IIA
[17,18].
Although all three isoforms are relevant in inflammation, group
V sPLA2 is a good candidate as it depends on both PS dependent
and hydrophobic docking mechanisms while also yielding
substantial arachidonic acid on leukocyte cell membranes
[14,15,19,20]. As reviewed by Murakami and Lambeau, in vivo
studies on group V sPLA2 have expanded on the understanding of
the role of group V sPLA2 in inflammation [21,22]. Recent studies
have shown group V to act in a proinflammatory fashion as
expected from the higher arachidonic acid release as compared to
group IIA, with group V being upregulated in asthma and
showing a proinflammatory dose-response relationship upon
aerosol administration of sPLA2-V [23]. Group V knock-out mice
have however revealed an anti-inflammatory effect in a disease
and tissue specific manner with decreased phagocytosis of IgG-
opsonized sheep red blood cells is impaired in group V 2/2
macrophages [24] and a protective effect in K/BxN autoantibody-
induced inflammatory arthritis [10]. Taken together, these
findings indicate that inflammation originating from excessive
sPLA2 activity should be addressed in a disease and tissue specific
manner to avoid adverse effects and that a systemic therapeutic
seems unlikely [25–27].
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minimized in quiescent cells by aminophospholipid translocases
which keep PS sequestered on the inner leaflet of the plasma
membranes of quiescent cells making it inaccessible to secretory
phospholipase A2 [28–31]. PS-exposure on the outer leaflet of the
plasma membrane is observed starting in early apoptosis as a
response to cellular stress [32,33]. Accordingly, it has been
demonstrated that PS-exposure influences the production of
arachidonic acid and thereby synthesis of proinflammatory
downstream products like leukotrienes and prostaglandins [34–
37]. These cyto- and chemokines are an important part of the
inflammatory cascade leading to increased vascular permeability,
recruitment of leukocytes, modulation of clotting, and induced
mast cell chemokine production [38]. Thus, inflammatory
function of secretory phospholipase A2 is linked to cell stimulation
and apoptosis via PS exposure.
Studies of the relationship of PS exposure to activity of PLA2’s
can be aided by reagents that report PS exposure as well as those
that block PS, preventing access of PLA2. Accordingly, it has been
shown that lactadherin (also called MFG-E8) is a sensitive and
selective probe for PS, with the bovine ortholog being the most
extensively studied [39–42]. Bovine lactadherin is a 409 amino
acid protein that can be purified as two glycosylation variants (47
and 52 kDa) from bovine milk. This peripheral bound membrane
protein is composed of two N-terminal EGF-like domains, with an
integrin binding RGD sequence in the EGF-2 domain [40,43].
Tandem discoidin-like domains, C1 and C2, mediate membrane
binding. Lactadherin exhibits a strong affinity for PS-containing
membranes with a Kd,0.08–4 nM [42,43]. Lactadherin also
displays stereospecific binding to phosphatidyl-L-serine and
preference for convex membranes. Membrane binding of
lactadherin is not Ca
2+-dependent which further improves its
value for monitoring and blocking exofacial PS [41,44–46]. There
are structural and functional similarities between the C1 and C2
domains of lactadherin and those of blood coagulation factors V
and VIII [39,41,42]. The structural homology of lactadherin with
factor V and factor VIII correlates with the capacity of lactadherin
to compete for PS-containing membrane binding sites and to
function as a potent anticoagulant [45]. The integrin and PS
binding enables lactadherin to operate as an opsonin, by bridging
apoptotic cells and vesicular debris, with exposed PS, to
phagocytic immune cells [47,48].
The research presented in this study aims at investigating the
extent to which lactadherin affects the activity of sPLA2.
Accordingly, activity was studied on vesicles of varying composi-
tion and size as well as on immortalized, human NB4 leukemia
cells. The results indicate that lactadherin inhibits the enzymatic
activity of phospholipase A2-V and, to a lesser extent, a snake
venom phospholipase A2.
Materials and Methods
Materials
Phosphatidylcholine (PC, egg yolk), phosphatidylethanolamine
(PE, egg yolk) and phosphatidyl-L-serine (PS porcine brain)
were purchased from Avanti Polar Lipids (AL, USA). 1,2-bis-
(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-unde-
canoyl)-sn-glycero-3-phosphocholine (bis-BODIPY FL C11-PC)
was from Life technologies (NY, USA). Fatty acid free bovine
serum albumin (BSA) was from EMD biosciences (Germany).
Human factor Xa and prothrombin were purchased from
Enzyme Research Laboratories (IN, USA), factor Va was
purchased from Haematologic Technologies Inc. (VT, USA),
and S-2238 thrombin chromogenic substrate from Diapharma
(OH, USA). Calcium ionophore A23187, propidium iodide (PI)
and Naja mossambica venom secretory phospholipase A2
(nmPLA2) were purchased from Sigma-Aldrich (MO, USA).
Recombinant human secretory phospholipase A2 group V
(hsPLA2-V) was purchased from Cayman chemical (MI, USA).
Bovine lactadherin was purified and labeled with fluorescein
isothiocyanate (FITC) as described previously [39,49]. Human
promyelocytic leukemia NB4 cells [50] were a generous gift
from Dr J. O’Kelly (Los Angeles, CA). Acrylodan-labeled
Intestinal Fatty Acid Binding Protein (ADIFAB) was purchased
from FFA Sciences, (CA, USA). All other chemicals (analytical
grade) were supplied by Sigma-Aldrich Corp. (St. Louis, Mo) or
Merck and Co. Inc (Whitehouse Station, NJ).
Lactadherin Purification
Lipid-free lactadherin was purified from fresh bovine milk
essentially as described previously [39]. Purity was checked by
SDS-PAGE showing the presence of only two bands at Mr 47 and
52 kDa corresponding to the two glycosylation variants, and by N-
terminal amino acid sequencing demonstrating more than 97
percent purity. Lactadherin concentration was determined by
measuring at A280 nm (e=77180 M
21 cm
21, calculated) and
stored at 280uC in 75 mM sodium phosphate, pH 7.0, 40 mM
KCl.
Phospholipid Vesicles
Sonicated small unilamellar and extruded large unilamellar
phospholipid vesicles (PLVs) of composition PS:PE:PC:bis-
BODIPY PC 4:20:75:1 were prepared as previously described
[41]. Phospholipid concentration was determined by elemental
phosphorous assay [51]. Vesicles were flash frozen in liquid
nitrogen, stored at 280uC, and thawed at 37uC within 2 hr of
experiments.
Spectrofluoroscopic Assay of Secretory PLA2 Activity on
Vesicles
The ability of lactadherin to inhibit sPLA2’s was determined
using various concentrations of purified lactadherin against
nmPLA2 and hsPLA2-V. Recombinant human phospholipase A2
group V was chosen due to the apparent involvement of hsPLA2–
V in eicosanoid synthesis. Phospholipase activity was measured on
a Peltier-thermostatted QMC-4-CW spectrofluorometer (PTI, NJ,
USA) with lex 488 nm and lem 515 nm. Slit widths were
0.5 mm for excitation and 1 mm for emission. Unless otherwise
indicated, phospholipid vesicles concentrations were 10 mM,
phospholipase concentration 0.06 U/ml, with enzyme kept on
ice and experiments done in duplicates. Measuring buffer was
HEPES (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 1 mM
Na2HPO4, 1.5 mM CaCl2 and MgCl2–pH 7.4) for vesicle
experiments.
PLVs were allowed to equilibrate at 4uC in 150 ml measuring
buffer for 5 min in the dark prior to addition of sPLA2 and
lactadherin in 150 ml, pre-cooled to 2uC. Vesicles were added via
an injection port so that fluorescence monitoring was not
interrupted. Fluorescence intensity dropped with injection, in
proportion to dilution of the PLV. Fluorescence intensity was
recorded in kinetic mode and analyzed for 6 min. at 4uC
immediately following the dilution-related decrease in intensity.
Fluorescence data were normalized to the value immediately
following PLA2 injection for display and analysis. When adding
lactadherin, the maximum activity of the inhibited reaction is
expressed against the uninhibited maximum activity.
Lactadherin Inhibits Secretory Phospholipase A2
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NB4 cells were maintained in RPMI 1640, 10% v/v fetal bovine
serum, 1% v/v 5,000 U/ml 5,000 mg/ml penicillin and strepto-
mycin (Life technologies, NY, USA) at 37uC, 5% CO2, humidified
atmosphere in a Symphony incubator (VWR, PA, USA). Optimal
growth rate and cell health was ensured by sub-culturing 24 hours
prior to experiments. All experiments were carried out between
passage 17 and 25. Washes were done in no phenol red no serum
RPMI1640 and centrifugation at 68 RCF with slow acceleration
and deceleration to avoid premature stress. Cells were treated with
calcium ionophore A23187 which in turn causes PS exposure on
the cytofacial surface [52,53]. This procedure has previously been
used successfully to mimic the PS exposure of apoptotic cells in
phospholipase assays [20,54,55] and produce a stressed phenotype
comparable to stimulated platelets [52]. A23187 was used at 6 mM
concentration and added to the cell suspension 10 minutes prior to
experiments. Optimal ionophore concentration and incubation
time were titrated by prothrombinase assay and FITC-labeled
lactadherin as described below. An alternate cell stress protocol
was employed to discount interactions between A23187 and
lactadherin. NB4 cells were stressed by incubation for 6 hours in
RPMI 1640 containing 40 mM etoposide before being washed
gently twice in 37uC no phenol red no serum RPMI 1640 as
previously described. Five times the original volume of cell
suspension was used (incubated cell suspension was 2 ml and wash
carried out using 2610 ml RPMI 1640) insuring that little
etoposide remained. The 40 mM etoposide concentration was
loosely based on Kaufmann et al. [56] and concentration and
incubation time verified by PI/FITC-lactadherin flow cytometry
as previously described.
Prothrombinase Assay of Cellular PS Exposure
PS exposure was measured using a two-step amidolytic substrate
assay for prothrombinase activity where the exposed membrane
PS is the limiting component of the prothrombinase complex [57].
The NB4 cells were gently washed, resuspended into reaction
buffer (No serum no phenol red RPMI1640, 0.005% v/v BSA)
and 100,000 cells added per well. A mixture of 0.5 nM Factor Xa
and 0.5 nM Factor Va in reaction buffer was added to each well
followed by substrate mix of 1 mM prothrombin and 1.5 mM
Ca
2+. The reaction was incubated for 5 min at room temperature
and terminated by adding stop buffer (20 mM Tris/HCl - pH 7.0,
0.005% BSA and 16 mM EDTA) to each well. The chromogenic
substrate S-2238 was added in each well to 115 mM and the speed
of color generation was measured at 405 nm using a VersaMAX
microplate reader (Molecular Devices, CA, USA) in kinetic mode,
3 second intervals. The reaction rate was found using Softmax Pro
and an appropriate timeframe (R
2.0.9).
Flow Cytometry Assay of Cellular PS Exposure
PI is traditionally used as an apoptosis marker [58], however as
the distinction between late stage apoptosis and necrosis can be
difficult, the combination of lactadherin and PI was used to allow
full control over the cell death pathway. Cell stress quantified by
PS exposure was monitored over time using FITC labeled
Lactadherin. Labeling was done as described previously [44,49]
with FITC-lactadherin and PI used as apoptosis marker in a
similar fashion as Vermes et al, Fadok et al a.o. [59–61]. 2610
6/
ml NB4 cells were washed gently in RPMI 1640 without serum or
phenol red and immediately treated using 6 mM A23187. Treated
cells were monitored for 90 minutes on a Becton Dickinson
LSRFortessa flow cytometer (BD biosciences, CA, USA) using
10 nM FITC-lactadherin and 2 mg/ml PI. Data processing was
done using FACS Diva and FCS Express.
Spectrofluoroscopic Assay of Secretory PLA2 Activity on
NB4 Cells
The rate of free fatty acid release by NB4 cells was monitored by
the fluorescence change of ADIFAB. Reactions were analyzed
with 100,000 cells per/ml in a 3:1 mix of HEPES-buffered saline
and RPMI1640 adjusted to 1.15 mM CaCl2. The reaction volume
was 300 mli n3 63 mm micro square cell cuvette at 37uC.
Fluorometer settings were lex 380 nm and lem 440 nm with slit
widths of 0.5 mm and 1.3 mm for excitation and emission,
respectively. Activity was initiated by injecting 250 ml sPLA2 in
50 ml cell solution over approx. 3 s. The final sPLA2 concentra-
tion was 0.06 U/ml. Due to the very fast initial reaction rate of the
stressed NB4 cells, the maximum activity was determined by
obtaining the slope by linear regression and extrapolating back the
last measured value prior to injection, usually 3–4 seconds.
Dataprocessing and Statistical Analysis
Standardized curves were fitted to a double exponential
association model:
Y~Ymaxdock   (1{e{Kdock X)zYmaxscoot   (1{e{Kscoot X) ð1Þ
Normalized curves (inhibition curves) were fitted to a double
exponential association model:
Y~Ymaxdock   (1{e{Kdock X)
zYmaxscoot   (1{e{Kscoot X)z1
ð2Þ
Initial rates versus substrate concentration was fitted to a
Michalis-Menten equation:
Y~
Vmax   X
KmzX
ð3Þ
As the reaction was very rapid on live cell membranes the initial
part of the curves were missing. The initial starting point of the
reaction curves was found by linear extrapolation back to the
original injection point. This was done to acquire the correct
maximal RFU value (DY) using:
Yext~
DY
DX
  (textract{tinject)z1 ð4Þ
All error bars display standard deviation and significance was
calculated using Welch’s t-test. Data processing was done in
Microsoft Excel 2010 and Graphpad Prism 5.
Results
We wished to determine whether lactadherin has the capacity
to inhibit activity of secretory PLA2. Accordingly, we developed
a real-time fluorescence assay and tested activity of a secretory
PLA2 from the venom of Naja mozambiqua (nmPLA2) toward
phospholipid vesicles containing 4% PS (Fig. 1). This membrane
composition is similar to the outer leaflet of apoptotic cells that
have undergone stimulation or stress [33,62]. Our results
indicated that nmPLA2 rapidly cleaves a fraction of the
fluorescent bis-BODIPY PC. At 37uC and at 25uC the
Lactadherin Inhibits Secretory Phospholipase A2
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it difficult to record the details. Thus, the experimental data
obtained for Figures 1–3 was obtained at 4uC, conditions under
which substrate cleavage occurred over 6 minutes. Addition of
lactadherin diminished the initial rate of substrate cleavage and
the plateau. Thus, lactadherin has the capacity to inhibit
activity of at least one secretory PLA2.
The relationship between nmPLA2 concentration and vesicle
concentration was explored in order to determine optimal
conditions for evaluating the inhibitory effect of lactadherin
(Fig. 2). The data were normalized to initial fluorescence to
emphasize the impact of varying phospholipid substrate with a
fixed phospholipase concentration. Results indicated that the
relative rate of substrate cleavage and the plateau are both
influenced by the initial phospholipid concentration (Fig. 2A).
Thus, initial phospholipase activity increased with substrate
concentration then slowed primarily in response to factor(s) other
than substrate depletion. This was explored by plotting the
combined Ymax obtained from a two-phase exponential association
fit (Eq. 1) versus phospholipid concentration (Fig. 2B). To verify
that the initial kinetic component was obeying Michaelis-Menten
kinetics under our experimental conditions, initial reaction rates
from 0 s to 5 s were measured and plotted against phospholipid
concentration (Fig. 2C) and fitted to a Michealis-Menten equation
(Eq. 3), R
2=0.96. Similar curves were obtained with hsPLA2-V
(data not shown). Thus, under these conditions the number of
sPLA2 molecules/membrane phospholipid influences the total
substrate cleavage as well as the initial rate. These results indicate
the relationship between the parameters of the assay and the rate
of substrate cleavage, enabling more quantitative testing of the
inhibition by lactadherin. Further experiments were designed to
primarily affect the initial, rapid component of phospholipase
activity.
We tested the inhibitory activity of lactadherin toward human
secretory PLA2 (Fig. 3). The results indicated progressive
inhibition at increasing concentrations of lactadherin with greater
than 95% inhibition at 75 nM lactadherin on 4% PS SUV
(Fig. 3A). A direct comparison of the inhibitory capacity of
lactadherin toward nmPLA2 vs. hsPLA2-V confirmed that 75 nM
lactadherin inhibits approx. 50% nmPLA2 activity while inhibiting
greater than 95% hsPLA2-V activity on 4% PS SUV (Fig. 3B).
Because the binding of lactadherin and PLA2’s are both sensitive
to membrane curvature [41,63] we asked whether inhibition by
lactadherin differed on extruded vesicles, with lesser membrane
Figure 1. Cleavage of fluorescent phospholipid by nmPLA2 and
inhibition by lactadherin. Sonicated phospholipid vesicles, 10 mM,
of composition PS:PE:PC:bbPC 4:20:75:1 were pre-incubated for 15
minutes in PBS, pH 7.2 at 22uC with, or without, pure lipid-free bovine
lactadherin before addition to a quartz cuvette of 363645 mm. Vesicles
were incubated for 5 minutes at 4uC in the Peltier-thermostatted
sample chamber of the fluorometer before adding nmPLA2 to a final
concentration of 0.06 U/ml. Reaction curves are normalized to baseline
fluorescence intensity before addition of phospholipase as per Eq. 2.
doi:10.1371/journal.pone.0077143.g001
Figure 2. Relationship between PLA2 concentration, phospho-
lipid concentration, and phospholipase activity. (A) Varying
concentrations of sonicated vesicles of composition PS:PE:PC:bbPC
4:20:75:1 were allowed to equilibrate at 4uC for 5 minutes before adding
0.125 U/ml nmPLA2. The resulting curve replicates were standardized
and fitted to a two-phase exponential association model (Eq. 1) and
solved for global rate constants (fitted curves). (B) Total Ymax obtained
from fitted curves was plotted against phospholipid concentrations and
fitted to a Michaelis-Menten equation. (C) The initial reaction rate was
obtained from the original datasets using linear regression from 0–5
seconds and plotted against phospholipid concentration. A Michaelis-
Menten equation was fitted to the data and of high fit quality. The
results indicate a saturable dose-response relationship. Experiments at
each phospholipid or phospholipase concentration were performed a
minimum of two times, and values averaged.
doi:10.1371/journal.pone.0077143.g002
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cence increase, in response to PLA2, with extruded vesicles was
approx. 3-fold greater than with sonicated vesicles, possibly related
to a greater degree of self-quenching by the BODIPY acyl chains
in the more tightly packed membrane cores of extruded vesicles.
Lactadherin inhibition studies indicated that lower concentrations
inhibit hsPLA2-V on extruded vesicles with IC50,4 nM vs.
18 nM on sonicated vesicles. The IC50 for nmPLA2 was also
lower, by approx. 2-fold on extruded vesicles. These results
indicate that lactadherin inhibits hsPLA2-V more effectively than
nmPLA2 and that the inhibitory concentration of lactadherin is
lower for vesicles with a lower degree of curvature.
We asked whether lactadherin might also inhibit PLA2 activity
on cell membranes (Fig. 4). For these experiments we utilized the
human promyelocytic leukemia cell line, NB4. These cells were
treated with 6 mM A23187 for 10 min at 22uC to stimulate pre-
apoptotic PS exposure (Fig. 4A). Prothrombinase activity support-
ed by the treated cells increased 3-fold compared to untreated
cells, indicating substantial PS exposure. As judged by flow
cytometry, these conditions resulted in 62% of cells meeting our
criteria of substantial PS exposure without permeability to
propidium iodide, while only 14% were apoptotic. To ensure
that membrane structure, and consequent susceptibility to PLA2
were not perturbed by the assay we utilized a different assay to
detect phospholipase activity. In this assay, the fluorescence of
fatty acid binding protein (ADIFAB) changes on binding to free
fatty acids that diffuse from the membrane after cleavage by PLA2.
The assay was controlled by measuring the rate of free fatty acid
release from cells that were quiescent, stressed, and stressed with
300 nM lactadherin in the absence of added PLA2. The rate of
free fatty acid release was low in the untreated cells and was not
significantly increased by addition of nmPLA2 or hsPLA2-V
(Fig. 4B and 4C - lower curves). Addition of nmPLA2 or hsPLA2 to
A23187 treated cells increased the rate of free fatty acid release by
6 and 13 fold respectively (top curves), indicating that these
enzymes have little activity on quiescent cells and much greater
activity on the membranes of pre-apoptotic cells. The rate of
phospholipid cleavage was faster with nmPLA2 than with hsPLA2-
V, but hsPLA2-V displayed a larger increase of the initial reaction
rate on highly PS exposing cells compared to nmPLA2.O n
stressed cells we observed a decrease in fluorescence after 20–40
seconds attributable to reacylation of free fatty acids as previously
described (not shown) [64,65].
Addition of lactadherin reduced the rate of free fatty acid
release (compare Fig. 4B and 4C top and middle curves). The
initial rate of nmPLA2 activity was reduced 45% by 300 nM
lactadherin on pre-apoptotic NB4 cells (Fig. 4D). Phospholipase
activity of hsPLA2-V on these cells was reduced by .70% (Fig. 4E).
To eliminate the interaction of lactadherin with A23187 as a cause
of the observed inhibition, cells were stressed with 40 mM
etoposide for 6 hours and run in a similar fashion. As seen in
Figure 4F, 300 nM lactadherin inhibited hsPLA2-V to much the
same extent as observed using ionophore treated cells. Adverse
effects like degradation or endocytosis was discounted by doing fast
runs on a Flex station 3 microplate reader using master enzyme
mixes (see figure S1 and S2). The inhibitory effect of lactadherin
on nmPLA2 and hsPLA2-V on plasma membranes exhibited
similar characteristics as those observed using small unilamellar
and large unilammellar vesicles with hsPLA2-V being more
readily inhibited. This indicates the validity of using 4% PS
vesicles as a reasonable pre-apoptotic plasma membrane model.
Together these results indicate that secretory phospholipase A2
activity is increased on pre-apoptotic cells and that lactadherin
inhibits the activity of the more promiscuous nmPLA2 as well as
the more fastidious hsPLA2-V on pre-apoptotic human leukemia
cell membranes.
Figure 3. Lactadherin inhibition of hsPLA2 vs. nmPLA2. (A)
Various concentrations of lactadherin were added to 10 mM phospho-
lipid vesicles with composition as described for Fig. 2. Phospholipid
vesicles were preincubated for 15 minutes with bovine lactadherin
before transfer to a quartz cuvette and cooling for 5 minutes at 4uC.
hsPLA2-V was added to a final concentration of 0.06 U/ml and the
activity monitored continuously as fluorescence emission at 515 nm.
Data were fitted to a double exponential model and fitted globally as
described in Fig. 2. Addition of lactadherin diminished both compo-
nents of enzyme activity. (B) Normalized net phospholipase activity on
sonicated PLVs after 400 s 6 SD are plotted as a function of lactadherin
concentration with uninhibited Ymax total as reference. (C) Experiments
like those in panel 3A were performed utilizing extruded PLV rather
than sonicated vesicles (not shown). Normalized phospholipase activity
after 400 s 6 SD are plotted as function of lactadherin concentration.
As seen in all panels, the PS sensitive hsPLA2-V is more readily blocked
by lactadherin. All experiments were performed at least twice and
results averaged for data displayed in panels B and C.
doi:10.1371/journal.pone.0077143.g003
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We have shown that lactadherin inhibits activity of secretory
phospholipase A2 on phospholipid vesicles and on cell membranes.
The degree of inhibition on phospholipid vesicles is lower for the
snake venom PLA2 than for a human secretory PLA2 associated
with inflammation. Susceptibility to PLA2 inhibition by lactad-
herin is also influenced by membrane composition and curvature.
These properties correlate to inhibition of phospholipase activity
on a human leukemia cell line following cell treatment with
A23187. Thus, lactadherin can inhibit secretory phospholipases A2
on the membranes of pre-apoptotic cells.
Our studies are in general agreement with studies indicating
that some phospholipase A2’s can be partially inhibited by annexin
A5 [66]. While the methodologies and the degree of phospholipid
digestion differed substantially between the prior reports and our
current report, our results are in qualitative agreement with the
finding that PS-binding membrane proteins can inhibit the
binding of phospholipases A2. It is noteworthy that the PS binding
of lactadherin is calcium independent, and phosphatidyl-L-serine
specific, in contrast to Annexin A5. These properties, and the
incomplete overlap between binding sites for lactadherin and
annexin V, likely contribute to the efficacy of lactadherin.
Our studies are in agreement with prior observations that
quiescent cell membranes support little or no activity of secretory
Figure 4. Inhibitory activity of lactadherin toward sPLA2’s on human leukemia cells. (A) NB4 cells were treated with 6 mM A23187 for 10
minutes at 22uC prior to addition of phospholipases. This treatment resulted in 61.6% pre-apoptotic cells. Phospholipase activity was detected as
release of free fatty acids using the ADIFAB reagent. Each curve was run as a set in quadruplicates using a single mixture of ADIFAB and PLA2. Curves
were run in separate sets. The initial reaction rates for nmPLA2 and hsPLA2-V were calculated by linear regression to the first 5 and 15 seconds
respectively, were r
2=0.85–0.95. (B) 0.06 U/ml nmPLA2 phospholipase activity on quiescent, stressed cells and stressed with 300 nM lactadherin were
measured. Lactadherin was added to the cell mix immediately before adding the ionophore, proceeding with 10 minute incubation. Control curves
from similar treated cells without added enzyme were subtracted as background and extrapolated Y values at injection point found using Eq. 3. Sum
curves of quadruplicate sets are displayed (C) The experiment was repeated as in panel B using 0.06 U/ml hsPLA2-V. The initial reaction rate was
calculated the same way as panel B. See panel 4D and 4E for quadruplicate results of nmPLA2 and hsPLA2-V respectively, SD displayed with
*denoting p,0.05 and **denoting p,0.001. To discount any adverse interactions between A23187 and lactadherin, cells were stressed using 40 mM
etoposide as described in materials and methods. As seen in Figure 4F, inhibition of hsPLA2-V to near quiescent levels by addition of 300 nM
lactadherin was observed, producing very similar inhibition ratios as found when using the quick, A23187 and lactadherin co-incubation protocol.
Statistical significance using a one-tailed T-test assuming unequal variance showed a significance of p,0.03.
doi:10.1371/journal.pone.0077143.g004
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enzymes are active on the membranes of apoptotic cells [64,67].
Part of the explanation is likely that PS is sequestered on the inner
leaflet of the resting cell membranes [29,68]. Cellular stress
induces phospholipid scrambling, which in turn exposes phospha-
tidylserine at the exofacial surface [34,69]. Experiments show that
PS exposing cells are target for inflammation-related secretory
phospholipases like group IIA [4,20] and V [20]. Exofacial PS
exposure recruits immune cells from increased eicosanoid
production via secretory phospholipase A2’s digestion of the
plasma membrane and aids macrophage phagocytosis directly
[32,70,71].
Secretory PLA2’s achieve efficacy via a 2-step mechanism [72].
First they bind to suitable sites on a membrane and subsequently
cleave the sn-2 bonds of successive phospholipid molecules without
dissociation from the membrane and re-binding [4,73]. Formation
of membrane binding sites for secretory PLA2 IIA and V is
increased by the content of negatively charged phospholipid
molecules and increased by convex curvature [65]. Binding sites
for lactadherin are proportional to membrane phosphatidylserine,
the major negatively charged membrane phospholipid, and
increased by convex membrane curvature [41], i.e. formation of
membrane binding sites for lactadherin is sensitive to parameters
that overlap with PLA2’s. These similarities lead us to hypothesize
that lactadherin primarily inhibits the initial binding step of
secretory PLA2’s. As such, the results suggest that the membrane
binding sites for nmPLA2, hsPLA2-V, and lactadherin overlap but
are not identical.
The findings in this study identify a new potential anti-
inflammatory mechanism for lactadherin. The primary, estab-
lished anti-inflammatory mechanism relates to its mechanism as
an opsonin for apoptotic cells. Engulfment by lactadherin-coated
cells promotes an anti-inflammatory response by phagocytes
[74,75]. A second potential anti-inflammatory mechanism is the
capacity to inhibit blood coagulation complexes on the mem-
branes of cells that are stimulated, stressed, or apoptotic [45]. This
study demonstrates that lactadherin may also modulate inflam-
mation through decreasing the activity of secretory phospholipase
A2’s. It appears possible that lactadherin may inhibit sPLA2’s on
the same cells in which it is mediating anti-inflammatory
phagocytosis during stress or apoptosis. Alternatively, secreted
lactadherin may bind to cells that are remote from phagocytes and
inhibit phospholipase activity independently from phagocytosis. In
the present study we utilized small and large unilamellar vesicles
and stressed NB4 cells to quantify the effect of lactadherin on
nmPLA2 and hsPLA2-V activity. PI and FITC-lactadherin was
used to monitor how many cells were in the different phases of
apoptosis. PI staining (membrane permeability) in conjunction
with PS exposure (stress and early apoptosis indicator) allows
differentiation between stress/early apoptosis, late stage apoptosis/
necrosis, cell debris and quiescent cells when combined with
forward and side scatter information [76–78]. Stressed/early
apoptotic cells stain for PS exposure, but not with PI and late stage
apoptotic cells stain for PS and PI. As seen in figure 4, the primary
part (,62%) of the cell population is pre-apoptotic (PS positive, PI
negative). The distinction between late stage apoptosis and
necrosis can be difficult and the measured ,14% PI/FITC-
lactadherin positive cells likely indicates the death rate of NB4 cells
subcultured 24 h before their use. However inhibiting phospho-
lipases on necrotic cells enforces our conclusion, that lactadherin
could function as an anti-inflammatory agent. In the presented
experiments we observed efficient inhibition at 300 nM (14.1 mg/
mL) lactadherin. This concentration is higher than that usually
found in serum with 3–17 ng/ml for healthy adults [79,80].
Several pathologic conditions have shown increased serum
concentrations 3–40 ng/ml for childhood-onset systemic lupus
patients and 13–33 ng/ml for type 2 diabetes mellitus [79,80].
Local concentrations in the microenvironment surrounding
lactadherin secreting phagocytes would however be expected to
be substantially higher. Furthermore, the strong preference of
sPLA2 group IIA to PS might be exploited to preferentially inhibit
group IIA in rheumatoid arthritis [10]. Further studies, utilizing
lactadherin fragments that mediate anti-sPLA2 activity indepen-
dent from pro-phagocytic activity will be required to distinguish
the importance of the anti-PLA2 activity in inflammation. These
studies may indicate whether lactadherin, or a molecule with
similar membrane binding properties, may have pharmaceutical
value as an anti-sPLA2 anti-inflammatory agent.
In summary, we show that lactadherin inhibits venom (group –
IA) and inflammatory (group –V) secretory phospholipase on both
artificial 4% PS membranes and plasma membranes of pre-
apoptotic cells. Further studies will be required to probe the
inhibitory mechanism. Further studies will also be required to
determine whether sPLA2 inhibition is a physiologic mechanism of
lactadherin function or whether lactadherin, or a lactadherin-like
molecule, might be adaptable for therapeutic inhibition of
sPLA2’s.
Supporting Information
Figure S1 Results of nmPLA2 on NB4 cells as monitored
by ADIFAB. Initial experiments and optimization was done using
a temperature controlled FlexStation 3 plate reader (Molecular
Devices, Sunnyvale, CA). Cells were washed by gentle centrifu-
gation at 68 RCF with slow acceleration and deceleration to avoid
cell stress, followed by resuspension in 37uC no phenol red no
serum RPMI 1640. 6 mM A23187 was added to the cell
suspension in all samples and 300 nM lactadherin was added
with A23187 in inhibition studies. 100,000 cells was dispensed per
well and allowed to incubate for 10 minutes before addition of
freshly made nmPLA2 master mix to a total concentration of
0.06 U/ml. For each 96-well plate, a column of controls were run
to reference the cellular stress levels of the cells in the vial used for
each run. This was done to exclude effects by different handling.
Using a plate reader allowed the exclusion of any time related
effects like degradation of the enzyme, ionophore, ADIFAB or
similar and the total run time was 3 minutes for master mix
preparation and 30 seconds until the reaction rate plateau was
reached equalling less than 5 minutes total. As seen in figure S1,
unstressed NB4 cells exhibited little enzymatic activity as compare
to the A23187 stressed cells. Inhibiting nmPLA2 with lactadherin
displayed similar results as observed in the spectrofluorometer with
a reduction of the initial reaction rate to roughly half. In all plate
reader experiments, quadruplicates where recorded and SD
displayed, but the late onset of the first read (14 second delay)
and the 2 second data point interval provided less than ideal data
for intricate analysis, due to the partial lack of the initial reaction
rate slope. A change to a high resolution spectrofluorometer
system was done subsequently.
(TIFF)
Figure S2 Results of hsPLA2-V on NB4 cells as moni-
tored by ADIFAB. Experiments using hsPLA2-V were carried
out in an identical manner as the nmPLA2 experiments. Although
the same 0.06 U/ml enzyme concentration was used, hsPLA2-V
displayed less activity on stressed membranes as compared to
nmPLA2. This behavior was later confirmed in higher resolution
datasets (Fig. 4D and 4E). As seen in Figure S2, hsPLA2-V activity
were almost completely abolished on stressed cells, however SD
Lactadherin Inhibits Secretory Phospholipase A2
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test assuming unequal variance showed a significance of p,0.026.
(TIFF)
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